| Diabetes Mellitus, Non-Insulin-Dependent

Jardiance vs Trulicity

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.
Deep comparison between: Jardiance vs Trulicity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsTrulicity has a higher rate of injection site reactions vs Jardiance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trulicity but not Jardiance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Jardiance
Trulicity
At A Glance
Oral
Once daily
SGLT2 inhibitor
SC injection
Once weekly
GLP-1 receptor agonist
Indications
  • Heart failure
  • Chronic Kidney Diseases
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.
Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.
Diabetes Mellitus, Non-Insulin-Dependent (Adults) Starting dose 0.75 mg SC once weekly; may increase to 1.5 mg after 4 weeks; further increases in 1.5 mg increments after at least 4 weeks on current dose; maximum 4.5 mg SC once weekly.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric, >=10 years) Starting dose 0.75 mg SC once weekly; if additional glycemic control needed, increase to maximum 1.5 mg SC once weekly after at least 4 weeks.
Contraindications
  • Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Serious hypersensitivity reaction to dulaglutide or any product component
Adverse Reactions
Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)
Most common (>=5%) Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia, fatigue
Serious Thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury, severe gastrointestinal reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration
Postmarketing Hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, cholestasis, elevated liver enzymes, hepatitis, anaphylactic reactions, angioedema, dysgeusia, dysesthesia, acute renal failure, alopecia
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.
Dulaglutide is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37) that activates the GLP-1 receptor in pancreatic beta cells, stimulating glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jardiance
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
View full coverage details ›
Trulicity
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Jardiance
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
Trulicity
  • Covered on 4 commercial plans
  • PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
Humana
Jardiance
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Trulicity
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Jardiance Savings Card
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Trulicity Savings Card
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
JardianceView full Jardiance profile
TrulicityView full Trulicity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.